Tag: migvax

QIRYAT SHMONA, ISRAEL, May 31, 2022 /EINPresswire.com/ — MigVax Ltd., a start-up developing an oral subunit vaccine against COVID-19, today announced that it has appointed Ran Amir as its new CEO. David Zigdon, MigVax’s first CEO and CEO of the MIGAL Galilee Research Institute, will continue playing an active role as MigVax’s President and Member of the Board of Directors. Read...

MigVax is one of two recipients for Coalition for Epidemic Preparedness Innovations funding awards A coalition funded by Bill Gates dedicated to fighting Covid awarded $4.3 million to an Israeli company for development of a variant-proof vaccine that comes in tablet form. Read...

Israel’s MigVax, the affiliate company established by Israeli scientists at the Migal Galilee Research Institute to develop a vaccine for the coronavirus, has received a $4.3 million award from Norway’s Coalition of Epidemic Preparedness Innovations (CEPI) to help support the initial development of its COVID-19 oral subunit vaccine tablet. Read...

Millions of pounds are being ploughed into developing variant-proof Covid vaccines that could be as effective against future strains as those circulating now. Scientists fear that current jabs could offer little protection against new versions of the Sars-Cov-2 virus – putting the world back to square one. The international Coalition for Epidemic Preparedness Innovations, to which the UK has contributed £260 million, is backing two projects. Israeli firm MigVax has been given £3.2 million to advance a vaccine pill known as MigVax-101, which would work as an easy-to-administer booster, and the University of Saskatchewan in Canada has been given £3.7 million to develop its own version. Read...